Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin

Molecular Cancer Therapeutics

Volumn 3, Issue 12, 2004, Pages 1525-1532

  Belenkov, Alexandre I ^a   Shenouda, George ^a   Rizhevskaya, Ekatarina ^a   Cournoyer, Denis ^a   Belzile, Jean Philippe ^a   Souhami, Luis ^a   Devic, Slobodan ^b   Chow, Terry Y K ^a,c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; JANUS KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SERUM; SOLID TUMOR; THERMAL EXPOSURE; TUMOR CELL LINE; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GLIOMA; HUMANS; JANUS KINASE 2; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RADIATION TOLERANCE; RADIATION, IONIZING; RECEPTORS, ERYTHROPOIETIN; TUMOR CELLS, CULTURED; TYRPHOSTINS; UTERINE CERVICAL NEOPLASMS;

EID: 12344335676     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kelleher DK, Matthiensen U, Thews O, Vaupel P. Tumor oxygenation in anemic rats: effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol 1995;34:379-4.
2. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229-37.
3. Murray D, Mirzayans R, Scott AL, Allalunis-Turner M J. Influence of oxygen on the radiosensitivity of human glioma cell lines. Am J Clin Oncol 2003;26:E169-77.
4. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
5. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
6. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647-57.
7. Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999;2:148-58.
8. Juul SE, Zhao Y, Dame JB, Du Y, Hutson AD, Christensen RD. Origin and fate of erythropoietin in human milk. Pediatr Res 2000;48:660-7.
9. Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 1999;70:1-6.
10. Acs G, Acs P, Beckwith SM, at al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
11. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307:999-1007.
12. Yasuda Y, Fujita Y, Masuda S, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002;23:1797-805.
13. Acs G, Chen M, Xu X, Acs P, Verma A, Koch C. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004;214(2):243-251. Also available from: http://www.sciencedirect.com.
14. Spivak JL. Recombinant erythropoietin. Annu Rev Med 1993;44: 243-53.
15. Tilbrook PA, Klinken SP. The erythropoietin receptor. Int J Biochem Cell Biol 1999;31:1001-5.
16. Watowich SS. Activation of erythropoietin signaling by receptor dimerization. Int J Biochem Cell Biol 1999;31:1075-88.
17. Miura O, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, Aoki N. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Blood 1994;84:1501-7.
18. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
19. Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 1998;10:271-8.
20. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993;74:227-36.
21. Zhuang H, Patel SV, He TC, Niu Z, Wojchowski DM. Dominant negative effects of a carboxy-truncated Jak2 mutant on Epo-induced proliferation and Jak2 activation. Biochem Biophys Res Commun 1994;204:278-83.
22. Chin H, Nakamura N, Kamiyama R, Miyasaka N, Ihle JN, Miura O. Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood 1996;88:4415-25.
23. Devemy E, Billat C, Haye B. Activation of Raf-1 and mitogen-activated protein kinases by erythropoietin and inositolphosphate-glycan in normal erythroid progenitor cells: involvement of protein kinase C. Cell Signal 1997;9:41-6.
24. Damen JE, Liu L, Cutler RL, Krystal G. Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein. Blood 1993;82:2296-303.
25. Miura O, Miura Y, Nakamura N, et al. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood 1994;84:4135-41.
26. Klingmuller U, Wu H, Hsiao JG, et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci U S A 1997;94:3016-21.
27. Tauchi T, Damen JE, Toyama K, Feng GS, Broxmeyer HE, Krystal G. Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis. Blood 1996;87:4495-501.
28. Belenkov AI, Paiement JP, Panasci LC, Monia BP, Chow TY. An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res 2002;62: 5888-96.
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 976;72:248-54.
30. McGuckin CP, Forraz N, Liu WM. Diaminofluorene stain detects erythroid differentiation in immature haemopoietic cells treated with EPO, IL-3, SCF, TGFβ1, MIP-1α and IFNγ. Eur J Haematol 2003;70: 106-14.
31. Lappin TR, Elder GE, Taylor T, McMullin MF, Bridges JM. Comparison of the mouse spleen cell assay and a radioimmunoassay for the measurement of serum erythropoietin. Br J Haematol 1988;70:117-20.
32. Hoffman R, Murnane MJ, Benz EJ Jr, et al. Induction of erythropoietic colonies in a human chronic myelogenous leukemia cell line. Blood 1979;54:1182-7.
33. Kitanaka A, Waki M, Kamano H, et al. Antisense src expression inhibits proliferation and erythropoietin-induced erythroid differentiation of K562 human leukemia cells. Biochem Biophys Res Commun 1994;201: 1534-40.
34. Neri LM, Bortul R, Tabellini G, et al. Erythropoietin-induced erythroid differentiation of K562 cells is accompanied by the nuclear translocation of phosphatidylinositol 3-kinase and intranuclear generation of phosphatidylinositol (3,4,5) trisphosphate. Cell Signal 2002;14:21-9.
35. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
36. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-36.
37. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem, Semin Hematol 1997;34:20-6.
38. Stuben G, Thews O, Pottgen C, Knuhmann K, Vaupel P, Stuschke M. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-50.
39. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514-20.
40. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
41. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811-20.
42. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999;94:1108-12.
43. Okutani Y, Kitanaka A, Tanaka T, et al. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 2001;20:6643-50.
44. Penta K, Sawyer ST. Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem 1995;270:31282-7.
45. Sawyer ST, Penta K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem 1996;271:32430-7.
46. Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004;23:981-90.
47. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
48. Lavey RS, Liu PY, Greer BE, et al. Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: A Southwest Oncology Group Study. Int J Radiat Oncol 2003;57:S190.
49. Pinel S, Barberi-Heyob M, Cohen-Jonathan E, et al. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys 2004;59:250-9.